首页>
外国专利>
The synergistic effect of tyrosine kinase inhibitors and chemical castration agents in the treatment of prostate cancer
The synergistic effect of tyrosine kinase inhibitors and chemical castration agents in the treatment of prostate cancer
展开▼
机译:酪氨酸激酶抑制剂和化学去势剂在前列腺癌治疗中的协同作用
展开▼
页面导航
摘要
著录项
相似文献
摘要
Described is a composition comprising a synergistic combination of a tyrosine kinase inhibitor and a chemical castration agent. The tyrosine kinase inhibitor is selected from a trkA inhibitor, a trkB inhibitor, a trkC inhibitor, or an indolocarbazole. The chemical castration agents include oestrogens; LHRH agonists, e.g., leuprolide acetate (LUPRON®) and goserelin acetate (ZOLADEX®); LHRH antagonists, e.g., ANTIDE® (Ares-Serono) and GANIRELIX® (Akzo Nobel); and antiandrogens, e.g., flutamide and nilutamide. The use of aforementioned tyrosine kinase inhibitors and chemical castration agents in the preparation of a medicament for inhibiting prostrate tumour progression in a mammal is also described. (62) Divided out of 502646
展开▼